2019 澳大利亚临床指南:儿童卒中亚急性康复

2019-02-10 国外儿科相关医学专家组(统称) 维多利亚亚急性儿童卒中咨询委员会官网

卒中是儿童十大死亡原因之一,超过一般生存者有长期残疾,本文主要针对儿童卒中亚急性康复的相关内容提出指导建议,内容涉及康复框架,运动功能康复,感觉功能康复,疼痛管理,吞咽困难和营养,语言功能康复,认知功能,心理、情感和行为功能,日常活动,娱乐休闲活动,学习教育等。

中文标题:

2019 澳大利亚临床指南:儿童卒中亚急性康复

英文标题:

The Subacute Rehabilitation of Childhood Stroke—CLINICAL GUIDELINE 2019

发布日期:

2019-02-10

简要介绍:

卒中是儿童十大死亡原因之一,超过一般生存者有长期残疾,本文主要针对儿童卒中亚急性康复的相关内容提出指导建议,内容涉及康复框架,运动功能康复,感觉功能康复,疼痛管理,吞咽困难和营养,语言功能康复,认知功能,心理、情感和行为功能,日常活动,娱乐休闲活动,学习教育等。 

拓展指南:卒中相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 澳大利亚临床指南:儿童卒中亚急性康复)] GetToolGuiderByIdResponse(projectId=1, id=c26251c001e16916, title=2019 澳大利亚临床指南:儿童卒中亚急性康复, enTitle=The Subacute Rehabilitation of Childhood Stroke—CLINICAL GUIDELINE 2019, guiderFrom=维多利亚亚急性儿童卒中咨询委员会官网, authorId=null, author=, summary=卒中是儿童十大死亡原因之一,超过一般生存者有长期残疾,本文主要针对儿童卒中亚急性康复的相关内容提出指导建议,内容涉及康复框架,运动功能康复,感觉功能康复,疼痛管理,吞咽困难和营养,语言功能康复,认知功能,心理、情感和行为功能,日常活动,娱乐休闲活动,学习教育等。 , cover=, journalId=null, articlesId=null, associationId=984, associationName=国外儿科相关医学专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sun Feb 10 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>卒中是儿童十大死亡原因之一,超过一般生存者有长期残疾,本文主要针对儿童卒中亚急性康复的相关内容提出指导建议,内容涉及康复框架,运动功能康复,感觉功能康复,疼痛管理,吞咽困难和营养,语言功能康复,认知功能,心理、情感和行为功能,日常活动,娱乐休闲活动,学习教育等。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>卒中</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=f24921c001e122b4" title="2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术" target=_blank>2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=406f51c001e11618" title="“移动卒中单元”中国专家共识2019" target=_blank>“移动卒中单元”中国专家共识2019</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=59c071c0016981c0" title="2019 AHA/ASA科学声明:新生儿和儿童卒中的管理" target=_blank>2019 AHA/ASA科学声明:新生儿和儿童卒中的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=bc4e71c00169eaf6" title="2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗" target=_blank>2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d3c1e1c0016956ba" title="卒中相关睡眠障碍评估与管理中国专家共识" target=_blank>卒中相关睡眠障碍评估与管理中国专家共识</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%8D%92%E4%B8%AD" target=_blank>有关卒中更多指南</a></ul>, tagList=[TagDto(tagId=17217, tagName=儿童卒中), TagDto(tagId=88115, tagName=亚急性康复)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=9, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6407, appHits=112, showAppHits=0, pcHits=4959, showPcHits=1760, likes=254, shares=6, comments=5, approvalStatus=1, publishedTime=Tue Mar 26 23:26:08 CST 2019, publishedTimeString=2019-02-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 26 23:26:08 CST 2019, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 00:09:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 澳大利亚临床指南:儿童卒中亚急性康复)])
2019 澳大利亚临床指南:儿童卒中亚急性康复
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=901303, encodeId=7070901303d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899968, encodeId=e5298999684a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:47 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363663, encodeId=fef23636635e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Thu Mar 28 01:19:41 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2020-11-22 911524993

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=901303, encodeId=7070901303d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899968, encodeId=e5298999684a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:47 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363663, encodeId=fef23636635e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Thu Mar 28 01:19:41 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2020-11-17 120cac51m28暂无昵称

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=901303, encodeId=7070901303d9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d86e1299318, createdName=911524993, createdTime=Sun Nov 22 23:44:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899968, encodeId=e5298999684a, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/a59b28b63198490ea85b1e5b3d13c2bf/1b1e0d03ca22467d8120443ebbc24c04.jpg, createdBy=35d22207591, createdName=120cac51m28暂无昵称, createdTime=Tue Nov 17 19:38:47 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363663, encodeId=fef23636635e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Thu Mar 28 01:19:41 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-03-28 SCI我的梦

    谢谢分享

    0